Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

Inclusion Criteria: * Subjects must provide written informed consent * Subjects must be 18 years of age or older * Subjects must have histologically confirmed ACC by the Department of Pathology at Dartmouth-Hitchcock Medical Center * Subjects must have inoperable disease * This is a first and/or second line study. Patients must have completed only one or fewer regimes of systemic therapy. They may have received one prior systemic therapy either: a) mitotane, or b)chemotherapy, or c) experimental therapy, or d) concurrent chemotherapy and mitotane, or e) no prior systemic therapy * Subjects must have a life expectancy of three or more months * If subjects have received some form of systemic therapy (e.g. chemotherapy or mitotane), they should have completed that systemic therapy at least 28 days before beginning Bevacizumab * All subjects of child-bearing potential(men and women) must agree to the use of effective means of contraception Exclusion Criteria: * Other co-existing malignancies or malignancies diagnosed within the last 5 years wtih the exception of basal cell carcinoma or cervical cancer in situ * Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy (except alopecia) * absolute neutrophil counts less than 1.5 x l,000,000,000/liter, or platelets less than 20.0 x 1,000,000,000/liter * As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory,cardiac, hepat…